In reply to the two Colin's,this announcement is purely an update to questions raised by shareholders in relation to the phase 11a trials regarding the performance of Xtoll and not a company update as such,which was given at the AGM 29/11/2011.This is an extract of what was announced at the AGM.------------"In recent days the company has been made aware of queries and concerns of shareholders relating to the development program and the rheumatoid arthritis clinical trial. An updated investor presentation and shareholder letter will be issued next week to address these queries. In closing, I thank those shareholders who have participated in providing constructive feedback to the company in recent months."
CBZ Price at posting:
16.5¢ Sentiment: Buy Disclosure: Held
